适应症-话题@MedSci

#适应症#

219篇内容 | 3002人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1336841, encodeId=455c1336841b4, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症, objectType=article, longId=208134, objectId=f8462081345b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8462081345b, replyNumber=0, likeNumber=96, createdTime=2021-03-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8462081345b, moduleTitle=默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8462081345b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336840, encodeId=e21513368405a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, objectType=article, longId=208131, objectId=91b320813104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b320813104, replyNumber=0, likeNumber=72, createdTime=2021-03-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b320813104, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b320813104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336839, encodeId=2f2a13368396d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=百济神州PD-1第6项适应症上市申请获受理，治疗非小细胞肺癌, objectType=article, longId=208127, objectId=ee4520812e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee4520812e11, replyNumber=0, likeNumber=62, createdTime=2021-03-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee4520812e11, moduleTitle=百济神州PD-1第6项适应症上市申请获受理，治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee4520812e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336838, encodeId=ae141336838be, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=特瑞普利单抗获批第2个适应症, objectType=article, longId=208119, objectId=1feb20811940, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1feb20811940, replyNumber=0, likeNumber=69, createdTime=2021-03-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1feb20811940, moduleTitle=特瑞普利单抗获批第2个适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1feb20811940)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336837, encodeId=1e01133683e4d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=黑色素瘤双靶、双适应症药物2020年医保价格正式实施，助益更多患者减轻负担, objectType=article, longId=208100, objectId=d0502081009c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0502081009c, replyNumber=0, likeNumber=69, createdTime=2021-03-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0502081009c, moduleTitle=黑色素瘤双靶、双适应症药物2020年医保价格正式实施，助益更多患者减轻负担, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0502081009c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336836, encodeId=c90f133683623, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, objectType=article, longId=207762, objectId=4aba20e76244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aba20e76244, replyNumber=0, likeNumber=83, createdTime=2021-03-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aba20e76244, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aba20e76244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336843, encodeId=685913368433d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, objectType=article, longId=207677, objectId=f31920e677cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31920e677cb, replyNumber=0, likeNumber=84, createdTime=2021-02-28, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31920e677cb, moduleTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31920e677cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336835, encodeId=1d4b133683508, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=新适应症获批！Humira冲击200亿美元有望, objectType=article, longId=207638, objectId=048f20e63867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=048f20e63867, replyNumber=0, likeNumber=52, createdTime=2021-02-28, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=048f20e63867, moduleTitle=新适应症获批！Humira冲击200亿美元有望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=048f20e63867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336834, encodeId=09ba13368349a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=“药王”HUMIRA（阿达木单抗）再获新适应症：FDA批准用于治疗儿童溃疡性结肠炎, objectType=article, longId=207623, objectId=dc2f20e62356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc2f20e62356, replyNumber=0, likeNumber=80, createdTime=2021-02-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc2f20e62356, moduleTitle=“药王”HUMIRA（阿达木单抗）再获新适应症：FDA批准用于治疗儿童溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc2f20e62356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336833, encodeId=168613368338f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格, objectType=article, longId=207609, objectId=8af020e60938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8af020e60938, replyNumber=0, likeNumber=72, createdTime=2021-02-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8af020e60938, moduleTitle=是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8af020e60938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336832, encodeId=edd71336832f5, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=阿斯利康在美国撤销Imfinzi的晚期膀胱癌适应症, objectType=article, longId=207493, objectId=cfff20e493bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfff20e493bc, replyNumber=0, likeNumber=74, createdTime=2021-02-24, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfff20e493bc, moduleTitle=阿斯利康在美国撤销Imfinzi的晚期膀胱癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfff20e493bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336831, encodeId=6b861336831fb, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌, objectType=article, longId=206130, objectId=192220613074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192220613074, replyNumber=0, likeNumber=56, createdTime=2021-01-24, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192220613074, moduleTitle=奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=192220613074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336829, encodeId=0fb3133682911, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=阿斯利康达格列净治疗慢性肾病适应症获FDA优先审评资格, objectType=article, longId=205578, objectId=ddb72055e8b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb72055e8b9, replyNumber=0, likeNumber=86, createdTime=2021-01-11, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb72055e8b9, moduleTitle=阿斯利康达格列净治疗慢性肾病适应症获FDA优先审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb72055e8b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336830, encodeId=104a13368302d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌, objectType=article, longId=205576, objectId=70432055e6e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70432055e6e8, replyNumber=0, likeNumber=72, createdTime=2021-01-11, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70432055e6e8, moduleTitle=恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70432055e6e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336828, encodeId=8fd41336828f8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=GSK贝利尤单抗新适应症获批, objectType=article, longId=204300, objectId=6d47204300dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d47204300dd, replyNumber=0, likeNumber=70, createdTime=2020-12-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d47204300dd, moduleTitle=GSK贝利尤单抗新适应症获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d47204300dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336827, encodeId=8518133682eae, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, objectType=article, longId=204111, objectId=394820411175, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=394820411175, replyNumber=0, likeNumber=98, createdTime=2020-12-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=394820411175, moduleTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=394820411175)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336826, encodeId=f0d61336826aa, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌, objectType=article, longId=204067, objectId=48f320406e75, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f320406e75, replyNumber=0, likeNumber=79, createdTime=2020-12-04, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f320406e75, moduleTitle=创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48f320406e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336825, encodeId=e60d133682569, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症, objectType=article, longId=203465, objectId=f0b620346555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b620346555, replyNumber=0, likeNumber=67, createdTime=2020-11-17, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b620346555, moduleTitle=默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b620346555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336824, encodeId=68d413368247e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=国家药监局批准卫材仑伐替尼治疗甲状腺癌，这是第二个适应症, objectType=article, longId=203201, objectId=fb9120320195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb9120320195, replyNumber=0, likeNumber=67, createdTime=2020-11-11, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb9120320195, moduleTitle=国家药监局批准卫材仑伐替尼治疗甲状腺癌，这是第二个适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb9120320195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336823, encodeId=4195133682386, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格, objectType=article, longId=202884, objectId=423720288436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423720288436, replyNumber=0, likeNumber=0, createdTime=2020-11-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423720288436, moduleTitle=早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423720288436)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适应症

2020-05-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症

2021-03-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症

2021-03-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

百济神州PD-1第6项适应症上市申请获受理，治疗非小细胞肺癌

2021-03-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

特瑞普利单抗获批第2个适应症

2021-03-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

黑色素瘤双靶、双适应症药物2020年医保价格正式实施，助益更多患者减轻负担

2021-03-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择

2021-03-02

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市

2021-02-28

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

新适应症获批！Humira冲击200亿美元有望

2021-02-28

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

“药王”HUMIRA（阿达木单抗）再获新适应症：FDA批准用于治疗儿童溃疡性结肠炎

2021-02-27

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格

2021-02-27

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

阿斯利康在美国撤销Imfinzi的晚期膀胱癌适应症

2021-02-24

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌

2021-01-24

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

阿斯利康达格列净治疗慢性肾病适应症获FDA优先审评资格

2021-01-11

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌

2021-01-11

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

GSK贝利尤单抗新适应症获批

2020-12-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌

2020-12-05

一叶知秋 (审核中...)

前往app查看评论内容

#适应症#

创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌

2020-12-04

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症

2020-11-17

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

国家药监局批准卫材仑伐替尼治疗甲状腺癌，这是第二个适应症

2020-11-11

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格

2020-11-05

科室
- - 订阅+
  - 更多科室
工具
服务